China is a region with a high prevalence of hepatitis B. The infection rate of HBV in the population is 60%, and the carrier rate of HBsAg is 10%-15%. It is estimated that 30%-50% of HBV infections are transmitted from mother to child. For newborns born to HBsAg-positive mothers, hepatitis B immunoglobulin (HBIG) should be injected as early as possible within 24 hours of birth, preferably within 12 hours of birth, and at the same time Hepatitis B vaccination at different sites can significantly improve the effectiveness of blocking mother-to-child transmission. However, for high-risk newborns of HBV-carrying mothers, the immunization failure rate using vaccine prophylaxis alone is >20%, and when HBV DNA is at high viral replication, immunization failure occurs in 40% of infants, and even when the combination of high-valent hepatitis B immune globulin (HBIG) and hepatitis B vaccine is applied, the immunization failure rate reaches 25%, and many studies have shown that high viral load is an independent risk for hepatitis B Many studies have shown that high viral load is an independent risk factor for failure of mother-to-child blockade. In order to maintain the stability of hepatitis B patients in the perinatal period, reduce pregnancy complications and decrease the rate of mother-to-child transmission of hepatitis B virus, perinatal antiviral therapy has been increasingly studied, and interferon and lamivudine have been shown to significantly reduce serum viral load in animal studies without toxic effects on animal embryos within a certain dose range. Interferon is contraindicated during pregnancy due to its anti-proliferative effect. The nucleoside antiviral drug lamivudine is classified by the US FDA as a class C drug for use during pregnancy and has been used in more studies for antiviral therapy during pregnancy. However, many pregnant women have many concerns about the use of drugs during pregnancy, and some researchers have focused on pre-pregnancy treatment. Yu Dekui et al. divided 136 women with HBsAg(+) into three groups and gave lamivudine antiviral treatment for 3 months before pregnancy and 1 month after stopping the drug; monthly intramuscular injections of hepatitis B immunoglobulin to pregnant women from the 4th to 9th month after pregnancy; HBIG 200 U at 28, 32 and 36 weeks after pregnancy; and no treatment before and during pregnancy. Pregnant infants in all three groups were given combined primary and passive immunization after birth. The results showed that the anti-HBs positivity rate of infants at 12 months of age in the three groups was 86.67%, 75.61% and 51.43%, respectively. In 2006, the U.S. FDA approved the marketing of tibivudine, a similar drug to lamivudine, as a class B drug in pregnancy, providing another option for antiviral therapy during pregnancy. Some studies have shown that telbivudine is superior to lamivudine in terms of antiviral efficacy, while the rate of primary treatment failure with telbivudine is significantly lower and the rate of drug resistance is reduced, but no studies of telbivudine treatment during pregnancy have been reported. Since there is no complete cure for chronic hepatitis B, and intrauterine infection with hepatitis B virus predisposes to chronic carriage of the virus, which can further develop into cirrhosis and even hepatocellular carcinoma. Several recommendations are made here for reference: 1. For pregnant women with very high viral load and abnormal liver function, pregnancy may be difficult to continue without appropriate treatment, and antiviral therapy may be recommended for such cases; 2. For patients with hepatitis B virus carriage only, but not high viral load, it is recommended that HBIG injection during pregnancy is still used to block it; 3. For pregnant women with very high viral load, but stable disease and normal liver function Try to avoid the use of drugs in early pregnancy when all organs of the embryo are developing. There is no information to prove the superiority of cesarean delivery over natural delivery in terms of mother-to-child blockade. Breastfeeding is generally not advocated for children born to HBV-DNA-positive mothers. The usual dietary advice: consume more mushroom foods, such as fungus, shiitake mushroom and mushroom, which can improve immunity; fish is rich in protein and easy to digest; consume more fresh vegetables and fruits to increase the content of VitC; do not smoke and drink alcohol to reduce the burden on the liver; consume less and no pickled foods and spicy with stimulating foods, forbid the use of fried foods and foods that are too greasy, and take a light diet as appropriate. Have pregnancy check-ups on time, keep a good mood and do not have a heart burden.